Journal
CURRENT CANCER DRUG TARGETS
Volume 17, Issue 1, Pages 89-97Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009616666161013101657
Keywords
Pancreatic cancer; nimotuzumab; predictive marker; EGFR; KRAS mutation
Categories
Funding
- National Science Foundation of China [81672327, 81372644, 81372645]
- FONG SHU FOOK TONG Foundation
- National Key Clinical Discipline (Oncology)
- innovation foundation of translational medicine of Shanghai Jiao Tong University School of Medicine [15ZH1002, 15ZH3001, 15ZH4001]
- Program for Outstanding Medical Academic Leader
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161410]
Ask authors/readers for more resources
Background: Nimotuzumab is shown to be efficacious in advanced pancreatic cancer treatment, but its predictive marker has not been established. Objective: To investigate the impact of EGFR and KRAS status on antitumor efficacy of nimotuzumab and to explore its underlying mechanism. Methods: EGFR expressions of pancreatic cancer cell lines, BxPC3, Panc-1, and Patu-8988, were analyzed by Western blot and immunocytochemistry, and KRAS status was determined by gene sequencing. Anti-tumor effect of nimotuzumab were evaluated in vitro and in vivo. The expressions of related molecules in EGFR pathway and IL-6 was analyzed by Western blot, immunohistochemistry, and/or real-time PCR. Results: BxPC3 cells had wild type KRAS and high-level EGFR; Panc-1 cells had mutant KRAS (G13A) and low-level EGFR; Patu-8988 cells had mutant KRAS (G12V) and high-level EGFR. Nimotuzumab did not affect cell proliferation or apoptosis in vitro. Growth of BxPC3 and Patu-8988 xenografts were significantly inhibited by nimotuzumab, but not Panc-1 xenografts, compared with that of the control group. Expression of EGFR in BxPC3 and Patu-8988 xenografts was significantly reduced by nimotuzumab. The IL-6 expression in BxPC3 and Patu-8988 xenografts was higher than that in Panc-1 xenografts in the control group, and was significantly reduced by nimotuzumab. Conclusion: Pancreatic cancer cells with EGFR high expression were more sensitive to nimotuzumab in vivo. KRAS status had no impact on anti-tumor efficacy of nimotuzumab in pancreatic cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available